Gene study aims to unlock secrets of progressive lung disease
NCT ID NCT07580053
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 250 Italian adults with genetic forms of pulmonary fibrosis to see how their lung function changes over time. Researchers will track breathing tests and compare patients who receive immune-modulating drugs with those who do not. The goal is to understand how inherited factors influence the speed of lung scarring.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors predict how lung fibrosis will progress based on a patient's genes, leading to more personalized care.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly improve health, and results may not apply to all patients with lung fibrosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Dec 2034
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with ILDs discussed in the multidisciplinary discussion to define FPF. Cases discussed will be documented using a standard CRF that detailed complete medical history including genetic test, physical examination, laboratory test results, pulmonary function test (PFT) results and, eventually, lung biopsy results and/or bronchoalveolar lavage (BAL) results. Pre-MDD diagnoses will be based on the referring pulmonologist's diagnosis and current consensus classification for ILDs. Post-MDD diagnosis will be classified according to Ryerson confidence terminology, with "confident diagnosis" reserved for \>90% clinical likelihood or a provisional diagnosis which was categorized as "high confidence" (70-89% likelihood) or "low confidence" (51-69% likelihood). Patients with less than 50% diagnostic confidence level post-MDD will be categorized as "unclassifiable ILD".
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * A HRCT scan consistent with ILD diagnosis * Age over 18 years old * A genetic test proved variant or a polymorphism consistent with a diagnosis of FPF * Ability to give informed consent for the inclusion in the study Exclusion Criteria: * Patients unable to perform pulmonary function tests
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Familial pulmonary fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Francesco Amati
Rozzano, Italy, 20089, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Patients and families build a living database of pulmonary fibrosis
- Can pulmonary fibrosis patients pull hard enough for their inhalers?
- Inhaled therapy aims to slow the march of progressive pulmonary fibrosis
- Sharper CT scans may solve a lung disease diagnostic puzzle
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can a new daily pill slow lung scarring in IPF?